Weiss Ratings Reaffirms "Sell (D-)" Rating for Werewolf Therapeutics (NASDAQ:HOWL)

Key Points

• Weiss Ratings reissued a "Sell (D-)" rating for Werewolf Therapeutics (NASDAQ:HOWL), indicating bearish sentiment for the stock.
• Despite the negative rating from Weiss, multiple brokerages, including Citigroup and Bank of America, continue to issue Buy ratings, with the stock currently having a consensus target price of $8.00.
• Shares of Werewolf Therapeutics traded down 2.6% to $1.88 amidst high trading volume, reflecting ongoing investor concern following recent earnings results.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other brokerages have also weighed in on HOWL. Citigroup restated a "buy" rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. JMP Securities reduced their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a report on Thursday, August 21st. Finally, Bank of America reduced their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Monday, August 25th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

Werewolf Therapeutics Trading Down 2.6%

Shares of HOWL traded down $0.05 during midday trading on Wednesday, reaching $1.88. The stock had a trading volume of 8,129,041 shares, compared to its average volume of 1,051,557. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $4.18. The company's fifty day simple moving average is $1.48 and its two-hundred day simple moving average is $1.21. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.10. As a group, research analysts anticipate that Werewolf Therapeutics will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HOWL. Jane Street Group LLC purchased a new position in Werewolf Therapeutics during the 2nd quarter worth $409,000. Marshall Wace LLP purchased a new position in Werewolf Therapeutics during the 2nd quarter worth $113,000. Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics during the 2nd quarter worth $92,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics during the 1st quarter worth $79,000. Finally, Nuveen LLC purchased a new position in Werewolf Therapeutics during the 1st quarter worth $71,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.